Rep. C. Scott Franklin Acquires Shares of Novo Nordisk A/S (NYSE:NVO)

Key Points

• Rep. C. Scott Franklin purchased $1,001–$15,000 of Novo Nordisk shares on August 26 in his Fidelity Roth IRA. He also bought shares of PepsiCo, McDonald’s and Accenture while selling positions in Alphabet, JPMorgan Chase and Apple.
• Novo Nordisk reported quarterly revenue of $11.98 billion and EPS of $0.94, while NVO shares opened at $43.23. Analysts broadly rate the stock a “Hold,” with a consensus price target of $64.94.
• The company has several potential growth catalysts, including European recommendations for FREHEMGO and Sogroya, an up-to-$1.4 billion oral-drug collaboration with Orbis, and an expanded AI partnership with Anthropic. However, halted cardiovascular trials and intensifying competition from Eli Lilly remain significant risks.

Representative C. Scott Franklin (Republican-Florida) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on September 17th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on August 26th. The trade occurred in the Representative's "FIDELITY ROTH IRA" account.

Representative C. Scott Franklin also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Accenture NYSE: ACN on 8/26/2026.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 8/20/2026.
• Sold $1,001 - $15,000 in shares of JPMorgan Chase & Co. NYSE: JPM on 8/20/2026.
• Sold $1,001 - $15,000 in shares of Apple NASDAQ: AAPL on 8/20/2026.

Novo Nordisk A/S Stock Up 0.1%

NVO stock opened at $43.23 on Friday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The company's 50 day simple moving average is $46.84 and its 200-day simple moving average is $43.81. The firm has a market capitalization of $193.04 billion, a PE ratio of 10.57, a P/E/G ratio of 1.42 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The business had revenue of $11.98 billion during the quarter. Equities analysts expect that Novo Nordisk A/S will post 3.53 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S's payout ratio is presently 20.05%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: European regulators issued positive recommendations for Novo’s hemophilia A therapy FREHEMGO (denecimig), supporting a potential 2026 launch and providing a new rare-disease revenue opportunity. EMA panel backs Novo Nordisk haemophilia A drug FREHEMGO
• Positive Sentiment: Sogroya received an important European recommendation for treating children with idiopathic short stature. Clinical data showed weekly treatment performed comparably with daily growth-hormone therapy, expanding the drug’s potential market. Sogroya wins EU recommendation
• Positive Sentiment: Novo agreed to collaborate with Orbis Medicines on oral cardiometabolic drugs in a deal worth up to $1.4 billion. The partnership could help Novo develop oral alternatives to injectable therapies and diversify its obesity and diabetes pipeline. Novo and Orbis sign oral-drug deal
• Positive Sentiment: An expanded partnership with Anthropic will use artificial intelligence to accelerate drug discovery and development. Investors view the initiative as a potential way to improve research productivity, though financial benefits are longer term. Novo expands AI push with Anthropic
• Positive Sentiment: Novo confirmed stable Ozempic supply in Canada amid elevated semaglutide demand, reducing near-term availability concerns in an important market. Novo confirms stable Ozempic supply in Canada
• Negative Sentiment: Novo halted two additional ziltivekimab cardiovascular trials after a late-stage study failed to reduce major adverse cardiovascular events. The setback weighs on efforts to diversify beyond the company’s core GLP-1 franchise. Novo halts two heart-drug trials
• Negative Sentiment: Analysts continue to cite intensifying competition from Eli Lilly, semaglutide-related risks and recent share-price weakness. The Anthropic deal also has no disclosed financial terms or productivity targets, limiting its immediate earnings impact. Novo stock outlook amid competition

Analyst Upgrades and Downgrades

Several research analysts recently commented on NVO shares. BMO Capital Markets restated a "market perform" rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Berenberg Bank set a $47.00 price target on Novo Nordisk A/S in a report on Wednesday, August 12th. Citigroup reissued a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. Finally, Zacks Research raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and an average price target of $64.94.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Wellington Altus USA Inc. acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at approximately $115,000. Smith Chas P & Associates PA Cpas lifted its holdings in Novo Nordisk A/S by 18.5% during the 2nd quarter. Smith Chas P & Associates PA Cpas now owns 950,151 shares of the company's stock valued at $45,550,000 after purchasing an additional 148,565 shares during the last quarter. Keystone Financial Planning Inc. acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $336,000. The Manufacturers Life Insurance Company boosted its stake in Novo Nordisk A/S by 22.6% in the second quarter. The Manufacturers Life Insurance Company now owns 229,607 shares of the company's stock worth $11,007,000 after purchasing an additional 42,361 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its position in Novo Nordisk A/S by 28.8% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 46,177 shares of the company's stock worth $2,214,000 after buying an additional 10,339 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida's 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida's 18th Congressional District. He declared candidacy for the 2026 election. Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012. Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin's career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.